news-tldr.com

The important facts, the open questions, and the sources — without the churn.

← Latest briefing

Health

Generic drug factory safety lapses and FDA exemptions for banned plants

ProPublica reports that inspectors documented unsanitary factory conditions and manipulated testing records, and that the FDA exempted at least 150 drugs from banned factories.

Published Nov 10, 2026 · 15:13 UTC1 reports

The short version

  • Inspectors reported dirty labs, mold, foul water, and bird feces on sterile equipment at generic drug factories, while the FDA redacts the names of medications made in those plants.[ProPublica]
  • Drug manufacturers manipulated and destroyed testing records, and ProPublica's testing with an independent lab found some generic tacrolimus pills contained less of the key ingredient.[ProPublica]
  • Over a dozen years, the FDA exempted at least 150 drugs or their ingredients from banned factories; the FDA says these exemptions are thoroughly evaluated but has not detailed how.[ProPublica]

Key facts

  • India produces about half of all generic drugs used in the United States, and pill bottle labels often omit where the drug was manufactured.[ProPublica]
  • The FDA redacts the names of medications made in factories with unsafe manufacturing conditions.[ProPublica]
  • Inspectors reported dirty labs, mold, foul water, and bird feces on boxes of sterile equipment at generic drug factories.[ProPublica]
  • Drug manufacturers manipulated and destroyed drug-testing records, including one case where an analyst poured acid on records in a trash bin.[ProPublica]
  • In testing ProPublica conducted with an independent lab, some generic tacrolimus pills contained a lower amount of the key ingredient.[ProPublica]
  • Over a dozen years, the FDA exempted at least 150 drugs or their ingredients from factories that had been banned from the United States.[ProPublica]
  • An FDA spokesperson said exemptions for banned factories are thoroughly evaluated through a multi-disciplinary approach but declined to say what those evaluations entailed.[ProPublica]

What remains uncertain

  • The FDA declined to describe how it evaluates exemptions for banned factories, so the basis for the at least 150 exemptions is not publicly explained.[ProPublica]
  • The tacrolimus findings say only that some pills contained less of the key ingredient, without establishing how many pills or manufacturers were affected; this comes from a single outlet's reporting and testing.[ProPublica]

Sources

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.